TY  - CHAP
M1  - Book, Section
TI  - Blood Disorders Year in Review
A1  - Papadakis, Maxine A.
A1  - McPhee, Stephen J.
A1  - Rabow, Michael W.
A1  - McQuaid, Kenneth R.
Y1  - 2023
N1  - 
T2  - Current Medical Diagnosis & Treatment 2023
AB  - For  patients  with  multiagent  refractory  disease,  CAR  T-cell  therapy  targeting  the  early  plasma  cell  antigen  BCMA  has  shown  response  rates  exceeding  70%  and  median  duration  of  response  of  over  11  months.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1193123451
ER  -